{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:19:13Z","timestamp":1787588353686,"version":"build-2736575974"},"reference-count":171,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1124\/pr.115.012203","type":"journal-article","created":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T02:54:59Z","timestamp":1458183299000},"page":"458-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["New Era of Lipid-Lowering Drugs"],"prefix":"10.1016","volume":"68","author":[{"given":"Philip J.","family":"Barter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry-Anne","family":"Rye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pr.115.012203_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1124\/pr.115.012203_bib2","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2009.11.069","article-title":"Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy","volume":"55","author":"Akdim","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.115.012203_bib3","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","article-title":"Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia","volume":"105","author":"Akdim","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1124\/pr.115.012203_bib4","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1172\/JCI200419992","article-title":"Foxo1 mediates insulin action on apoC-III and triglyceride metabolism","volume":"114","author":"Altomonte","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.115.012203_bib5","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1172\/JCI114558","article-title":"Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit","volume":"85","author":"Badimon","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.115.012203_bib6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1124\/pr.115.012203_bib7","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.115.012203_bib8","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","article-title":"Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia","volume":"115","author":"Ballantyne","year":"2015","journal-title":"Am J Cardiol"},{"issue":"Suppl","key":"10.1124\/pr.115.012203_bib9","doi-asserted-by":"crossref","first-page":"10E","DOI":"10.1016\/j.amjcard.2009.09.014","article-title":"Lessons learned from the Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) trial","volume":"104","author":"Barter","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1124\/pr.115.012203_bib10","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/ATVBAHA.107.148817","article-title":"Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?","volume":"28","author":"Barter","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib12","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1194\/jlr.R024075","article-title":"Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk","volume":"53","author":"Barter","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib13","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.012203_bib14","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","article-title":"PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses","volume":"55","author":"Benn","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.115.012203_bib15","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib16","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1172\/JCI42946","article-title":"Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease","volume":"121","author":"Besler","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.115.012203_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1124\/pr.115.012203_bib18","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1073\/pnas.91.10.4427","article-title":"Prevention of ischemia-induced ventricular fibrillation by omega 3 fatty acids","volume":"91","author":"Billman","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.115.012203_bib19","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1161\/01.CIR.0000153341.46271.40","article-title":"Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects","volume":"111","author":"Boekholdt","year":"2005","journal-title":"Circulation"},{"key":"10.1124\/pr.115.012203_bib21","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9","volume":"49","author":"Careskey","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib23","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1194\/jlr.M600135-JLR200","article-title":"Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice","volume":"47","author":"Casquero","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1124\/pr.115.012203_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1194\/jlr.M100440-JLR200","article-title":"Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice","volume":"44","author":"Cazita","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.atherosclerosis.2015.01.014","article-title":"Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature","volume":"239","author":"Cefal\u00f9","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1124\/pr.115.012203_bib27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1194\/jlr.M500349-JLR200","article-title":"Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action","volume":"47","author":"Clark","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib28","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"10.1124\/pr.115.012203_bib30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/bjo.2006.101022","article-title":"Prevalence of reticular pseudodrusen in age-related macular degeneration with newly diagnosed choroidal neovascularisation","volume":"91","author":"Cohen","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1124\/pr.115.012203_bib31","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/FJC.0b013e3181cf03cb","article-title":"Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition","volume":"55","author":"Connelly","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.115.012203_bib32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1124\/pr.115.012203_bib33","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1194\/jlr.M400018-JLR200","article-title":"Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome","volume":"45","author":"Cramer","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1124\/pr.115.012203_bib36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"10.1124\/pr.115.012203_bib37","doi-asserted-by":"crossref","first-page":"27i","DOI":"10.1016\/j.amjcard.2005.12.024","article-title":"Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids","volume":"98","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1124\/pr.115.012203_bib38","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"10.1124\/pr.115.012203_bib39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.atherosclerosis.2011.04.001","article-title":"The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins","volume":"217","author":"Di Bartolo","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1124\/pr.115.012203_bib40","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0022-2275(20)35728-X","article-title":"Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans","volume":"34","author":"Dietschy","year":"1993","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib41","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/327632a0","article-title":"Cloning and sequencing of human cholesteryl ester transfer protein cDNA","volume":"327","author":"Drayna","year":"1987","journal-title":"Nature"},{"key":"10.1124\/pr.115.012203_bib42","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/CIRCRESAHA.116.305485","article-title":"HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export","volume":"116","author":"Du","year":"2015","journal-title":"Circ Res"},{"key":"10.1124\/pr.115.012203_bib43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/01.CIR.94.4.713","article-title":"Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits","volume":"94","author":"Duverger","year":"1996","journal-title":"Circulation"},{"key":"10.1124\/pr.115.012203_bib44","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S0021-9258(19)40033-1","article-title":"Rat ATP citrate-lyase. Molecular cloning and sequence analysis of a full-length cDNA and mRNA abundance as a function of diet, organ, and age","volume":"265","author":"Elshourbagy","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.012203_bib45","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1124\/pr.115.012203_bib46","doi-asserted-by":"crossref","first-page":"11067","DOI":"10.1021\/bi901564g","article-title":"Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1","volume":"48","author":"Favari","year":"2009","journal-title":"Biochemistry"},{"key":"10.1124\/pr.115.012203_bib47","doi-asserted-by":"crossref","first-page":"36912","DOI":"10.1074\/jbc.274.52.36912","article-title":"Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice","volume":"274","author":"F\u00f6ger","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.012203_bib48","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.115.012203_bib49","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.115.012203_bib50","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2840-12-82","article-title":"Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists","volume":"12","author":"Fruchart","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1124\/pr.115.012203_bib52","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib53","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib54","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib55","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1124\/pr.115.012203_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.cb.01.110185.000245","article-title":"Receptor-mediated endocytosis: concepts emerging from the LDL receptor system","volume":"1","author":"Goldstein","year":"1985","journal-title":"Annu Rev Cell Biol"},{"key":"10.1124\/pr.115.012203_bib57","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ Res"},{"key":"10.1124\/pr.115.012203_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010682","article-title":"A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo","volume":"5","author":"Gupta","year":"2010","journal-title":"PLoS One"},{"key":"10.1124\/pr.115.012203_bib59","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0305-0491(82)90252-8","article-title":"Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species","volume":"71","author":"Ha","year":"1982","journal-title":"Comp Biochem Physiol B"},{"key":"10.1124\/pr.115.012203_bib60","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1172\/JCI118255","article-title":"Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene","volume":"96","author":"Hayek","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.115.012203_bib61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00544015","article-title":"Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects","volume":"25","author":"Heller","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.115.012203_bib62","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/70956","article-title":"Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein","volume":"5","author":"Herrera","year":"1999","journal-title":"Nat Med"},{"key":"10.1124\/pr.115.012203_bib63","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/S0021-9258(18)61650-3","article-title":"Purification and characterization of a human plasma cholesteryl ester transfer protein","volume":"262","author":"Hesler","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.012203_bib64","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/ATVBAHA.110.205153","article-title":"Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency","volume":"30","author":"Hildebrand","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem Sci"},{"issue":"Suppl","key":"10.1124\/pr.115.012203_bib66","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib67","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"10.1124\/pr.115.012203_bib68","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1210\/en.2008-1512","article-title":"Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition","volume":"150","author":"Hu","year":"2009","journal-title":"Endocrinology"},{"key":"10.1124\/pr.115.012203_bib69","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1194\/jlr.M000422","article-title":"Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor","volume":"51","author":"Huang","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib70","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.111.000232","article-title":"Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease","volume":"1","author":"Jensen","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1124\/pr.115.012203_bib71","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1194\/jlr.M700443-JLR200","article-title":"Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol-regulatory element binding protein-2","volume":"49","author":"Jeong","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib72","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.jacc.2012.07.045","article-title":"Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects","volume":"60","author":"Johannsen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.115.012203_bib73","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.ATV.19.3.472","article-title":"Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3","volume":"19","author":"Jong","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib74","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib75","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.115.012203_bib76","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"key":"10.1124\/pr.115.012203_bib77","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/CIRCULATIONAHA.106.622514","article-title":"Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells","volume":"114","author":"Kawakami","year":"2006","journal-title":"Circulation"},{"key":"10.1124\/pr.115.012203_bib78","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/CIRCULATIONAHA.105.591743","article-title":"Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells","volume":"113","author":"Kawakami","year":"2006","journal-title":"Circulation"},{"key":"10.1124\/pr.115.012203_bib79","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1124\/pr.115.012203_bib80","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1093\/eurheartj\/ehv291","article-title":"Potent peroxisome proliferator-activated receptor-\u03b1 agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome","volume":"36","author":"Khera","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1124\/pr.115.012203_bib81","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0014-5793(76)80145-7","article-title":"Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase","volume":"65","author":"Kinnunen","year":"1976","journal-title":"FEBS Lett"},{"key":"10.1124\/pr.115.012203_bib82","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"10.1124\/pr.115.012203_bib83","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1124\/pr.115.012203_bib84","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"10.1124\/pr.115.012203_bib85","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/eurheartj\/ehu319","article-title":"Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin","volume":"36","author":"K\u00fchnast","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1124\/pr.115.012203_bib86","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib87","doi-asserted-by":"crossref","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","article-title":"Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets","volume":"288","author":"Larsson","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.012203_bib88","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10545-013-9665-4","article-title":"Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management","volume":"37","author":"Lee","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1124\/pr.115.012203_bib89","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/mt.2011.260","article-title":"PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates","volume":"20","author":"Lindholm","year":"2012","journal-title":"Mol Ther"},{"key":"10.1124\/pr.115.012203_bib90","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1124\/pr.115.012203_bib91","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1161\/01.ATV.0000080687.94313.67","article-title":"Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db\/db mice","volume":"23","author":"MacLean","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib92","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s11745-999-0445-x","article-title":"Eicosapentaenoic and docosahexaenoic acid affect mitochondrial and peroxisomal fatty acid oxidation in relation to substrate preference","volume":"34","author":"Madsen","year":"1999","journal-title":"Lipids"},{"key":"10.1124\/pr.115.012203_bib93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/364073a0","article-title":"Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein","volume":"364","author":"Marotti","year":"1993","journal-title":"Nature"},{"key":"10.1124\/pr.115.012203_bib94","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.115.012203_bib95","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.115.012203_bib96","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1172\/JCI80025","article-title":"Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects","volume":"125","author":"Millar","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.115.012203_bib97","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1194\/jlr.M600332-JLR200","article-title":"Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits","volume":"48","author":"Morehouse","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib98","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1600-0854.2007.00562.x","article-title":"The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR","volume":"8","author":"Nassoury","year":"2007","journal-title":"Traffic"},{"key":"10.1124\/pr.115.012203_bib99","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/hc0302.103711","article-title":"Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol","volume":"105","author":"Navab","year":"2002","journal-title":"Circulation"},{"key":"10.1124\/pr.115.012203_bib100","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1161\/CIRCULATIONAHA.108.790733","volume":"118","author":"Nicholls","year":"2008","journal-title":"Circulation"},{"key":"10.1124\/pr.115.012203_bib101","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1194\/jlr.M008706","article-title":"Modulating cholesteryl ester transfer protein activity maintains efficient pre-\u03b2-HDL formation and increases reverse cholesterol transport","volume":"51","author":"Niesor","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib102","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00125-008-0975-2","article-title":"Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus","volume":"51","author":"Nieuwdorp","year":"2008","journal-title":"Diabetologia"},{"key":"10.1124\/pr.115.012203_bib103","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1124\/pr.115.012203_bib104","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCGENETICS.114.000748","article-title":"Circulating cholesteryl ester transfer protein and coronary heart disease: mendelian randomization meta-analysis","volume":"8","author":"Niu","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1124\/pr.115.012203_bib105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35018119","article-title":"A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits","volume":"406","author":"Okamoto","year":"2000","journal-title":"Nature"},{"key":"10.1124\/pr.115.012203_bib106","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1194\/jlr.M300253-JLR200","article-title":"Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease","volume":"44","author":"Olivieri","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib107","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.012203_bib108","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib109","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1161\/01.ATV.19.4.1105","article-title":"Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression","volume":"19","author":"Plump","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib110","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1073\/pnas.91.20.9607","article-title":"Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse","volume":"91","author":"Plump","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.115.012203_bib111","first-page":"1135","article-title":"The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol","volume":"7","author":"Poirier","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/pr.115.012203_bib112","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1124\/pr.115.012203_bib113","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1124\/pr.115.012203_bib114","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCGENETICS.108.817304","article-title":"Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women\u2019s Genome Health Study","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1124\/pr.115.012203_bib115","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/01.ATV.20.9.2106","article-title":"Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis","volume":"20","author":"Rittershaus","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib116","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib117","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","article-title":"Dysfunctional HDL and atherosclerotic cardiovascular disease","volume":"13","author":"Rosenson","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"10.1124\/pr.115.012203_bib118","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib119","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/353265a0","article-title":"Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI","volume":"353","author":"Rubin","year":"1991","journal-title":"Nature"},{"key":"10.1124\/pr.115.012203_bib120","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib121","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1194\/jlr.R039297","article-title":"Cardioprotective functions of HDLs","volume":"55","author":"Rye","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib122","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib123","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1194\/jlr.M800622-JLR200","article-title":"Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo","volume":"50","author":"Sacks","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib124","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1124\/pr.115.012203_bib125","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib126","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ Res"},{"key":"10.1124\/pr.115.012203_bib127","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.115.012203_bib128","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/01.CIR.97.8.780","article-title":"Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice","volume":"97","author":"Shah","year":"1998","journal-title":"Circulation"},{"key":"10.1124\/pr.115.012203_bib129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/365065a0","article-title":"Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia","volume":"365","author":"Sharp","year":"1993","journal-title":"Nature"},{"key":"10.1124\/pr.115.012203_bib130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0014-2999(01)01419-4","article-title":"MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion","volume":"431","author":"Shiomi","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.115.012203_bib131","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/eurheartj\/ehr348","article-title":"Torcetrapib impairs endothelial function in hypertension","volume":"33","author":"Simic","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1124\/pr.115.012203_bib132","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1161\/01.CIR.103.15.1949","article-title":"Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study","volume":"103","author":"Sirtori","year":"2001","journal-title":"Circulation"},{"key":"10.1124\/pr.115.012203_bib133","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1161\/ATVBAHA.112.251306","article-title":"Mechanisms of lipoprotein(a) pathogenicity: prothrombotic, proatherosclerotic, or both?","volume":"32","author":"Spence","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib134","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1124\/pr.115.012203_bib135","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1172\/JCI117717","article-title":"Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates","volume":"95","author":"Staels","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.115.012203_bib136","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/MOL.0000000000000182","article-title":"Proprotein convertases in atherogenesis","volume":"26","author":"Stawowy","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1124\/pr.115.012203_bib137","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"10.1124\/pr.115.012203_bib138","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1124\/pr.115.012203_bib139","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1056\/NEJMoa1405386","article-title":"Inactivating mutations in NPC1L1 and protection from coronary heart disease","volume":"371","author":"Stitziel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib140","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1074\/jbc.273.9.5033","article-title":"Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits","volume":"273","author":"Sugano","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.115.012203_bib141","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1124\/pr.115.012203_bib142","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.bbrc.2011.05.154","article-title":"Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter","volume":"410","author":"Sviridov","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.115.012203_bib143","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/ATVBAHA.110.222000","article-title":"Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages","volume":"31","author":"Tabet","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib144","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/ATVBAHA.109.200196","article-title":"The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro","volume":"30","author":"Tabet","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib145","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","article-title":"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial","volume":"35","author":"Tardif","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1124\/pr.115.012203_bib146","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"JAMA"},{"key":"10.1124\/pr.115.012203_bib148","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.115.012203_bib149","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(03)12468-3","article-title":"Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial","volume":"361","author":"Thies","year":"2003","journal-title":"Lancet"},{"key":"10.1124\/pr.115.012203_bib150","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1001\/jama.299.23.2777","article-title":"Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk","volume":"299","author":"Thompson","year":"2008","journal-title":"JAMA"},{"key":"10.1124\/pr.115.012203_bib151","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1124\/pr.115.012203_bib152","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1124\/pr.115.012203_bib153","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/01.ATV.0000216600.37436.cf","article-title":"High-density lipoproteins enhance progenitor-mediated endothelium repair in mice","volume":"26","author":"Tso","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib154","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis","volume":"62","author":"Urban","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.115.012203_bib155","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1194\/jlr.M057794","article-title":"Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9","volume":"56","author":"van der Tuin","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib156","doi-asserted-by":"crossref","first-page":"554","DOI":"10.7326\/0003-4819-130-7-199904060-00003","article-title":"The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial","volume":"130","author":"von Schacky","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.115.012203_bib157","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.jacc.2009.12.067","article-title":"A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome","volume":"55","author":"Waksman","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.115.012203_bib158","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI111711","article-title":"Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III","volume":"75","author":"Wang","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.115.012203_bib159","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1172\/JCI113806","article-title":"Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism","volume":"82","author":"Weintraub","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.115.012203_bib160","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib161","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1161\/01.ATV.0000243925.65265.3c","article-title":"Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice","volume":"26","author":"Westerterp","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib162","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1126\/science.1439810","article-title":"Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia","volume":"258","author":"Wetterau","year":"1992","journal-title":"Science"},{"key":"10.1124\/pr.115.012203_bib163","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0022-2275(20)34342-X","article-title":"Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver","volume":"26","author":"Windler","year":"1985","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.115.012203_bib164","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1161\/CIRCRESAHA.111.300104","article-title":"High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3\u03b2-hydroxysteroid-\u039424 reductase expression and inducing heme oxygenase-1","volume":"112","author":"Wu","year":"2013","journal-title":"Circ Res"},{"key":"10.1124\/pr.115.012203_bib165","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijcard.2015.07.014","article-title":"Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis","volume":"199","author":"Wu","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1124\/pr.115.012203_bib166","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/ATVBAHA.114.304747","article-title":"Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit","volume":"35","author":"Wu","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib167","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1101\/gad.8.16.1910","article-title":"Sterol-resistant transcription in CHO cells caused by gene rearrangement that truncates SREBP-2","volume":"8","author":"Yang","year":"1994","journal-title":"Genes Dev"},{"key":"10.1124\/pr.115.012203_bib168","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1124\/pr.115.012203_bib169","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/ATVBAHA.110.207142","article-title":"Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib","volume":"30","author":"Yvan-Charvet","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib170","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/ATVBAHA.106.138347","article-title":"Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL","volume":"27","author":"Yvan-Charvet","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.115.012203_bib171","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"10.1124\/pr.115.012203_bib147","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724011840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724011840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pr.115.012203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T10:46:30Z","timestamp":1739875590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724011840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":171,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0031699724011840"],"URL":"https:\/\/doi.org\/10.1124\/pr.115.012203","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Era of Lipid-Lowering Drugs","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pr.115.012203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}